NICE, drug-eluting stents and the limits of trial data

Mohindra, R
March 2009
Heart;Mar2009, Vol. 95 Issue 6, p505
Academic Journal
No abstract available.


Related Articles

  • Oral therapy to prevent restenosis is promising.  // Formulary;Jan2004, Vol. 39 Issue 1, p46 

    Reveals results of clinical trials made on oral cardiovascular drug called cilostazol. Alternative to drug-eluting stents to limit restenosis; Overall in-segment restenosis rates.

  • Balancing Efficacy and Safety of Drug-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention. Jeremias, Allen; Kirtane, Ajay // Annals of Internal Medicine;2/5/2008, Vol. 148 Issue 3, p234 

    Drug-eluting stents reduce the occurrence of in-stent restenosis and the need for subsequent target vessel revascularization compared with bare-metal stents. However, the safety of drug-eluting stents has been called into question because of an apparent increase in late stent thrombosis, a...

  • Cardiology.  // Africa Health;Jul2011, Vol. 33 Issue 5, p59 

    The article reports on a clinical trial comparing two new generation drug-eluting coronary stents, and a meta-analysis of data revealing a 1% decrease in myocardian infarction risk with angiotensin receptor blocker (ARB).

  • Stenting.  // Current Medical Literature: Cardiology;2007, Vol. 26 Issue 2, p53 

    The article presents editor's notes on research about stenting. The research "Late Clinical Events After Clopidogrel Discontinuation May Limit the Benefit of Drug-Eluting Stents: An Observational Study of Drug-Eluting Versus Bare-Metal Stents," by M. Pfisterer proves that cases of late cardiac...

  • The Enigma of Drug-Eluting Stents. Harrington, Robert A.; Ohman, E. Magnus // JAMA: Journal of the American Medical Association;5/9/2007, Vol. 297 Issue 18, p2028 

    This editorial examines drug-eluting stents. The rapid approval of stents and short term trials did little to prepare physicians and patients for the long-term issues that have been arising. The author maintains that drug-eluting stenting is clearly a breakthrough in the prevention of...

  • Use of Registries to Complement Clinical Trials in Renal Artery Stenting. Rajmony, Pannu; Sanjay, Misra // Angiology;Jun2012, Vol. 63 Issue 3, p161 

    The authors discuss several studies to support their opinion that the use of registry data should complement clinical trials in renal artery atherosclerotic disease management. They offer a brief history of the treatment of atherosclerotic blockages with angioplasty, coronary bypass surgery...

  • Drug-Eluting Stents in Acute Myocardial Infarction: Is Science Catching Up With Practice? Cohen, Mauricio G.; Ohman, E. Magnus // JAMA: Journal of the American Medical Association;5/4/2005, Vol. 293 Issue 17, p2154 

    Comments on the use of drug-eluting stents in the treatment of myocardial infarction. Impact of drug-eluting stents on the success of interventional cardiology; History of the use of drug-eluting stents in clinical practice in the U.S.; Potential efficacy of drug-eluting stents in the treatment...

  • The pros and cons of drug-eluting stents. Asch-Goodkin, Judith; Kaplan, Deborah // Patient Care;Nov2006, Vol. 40 Issue 11, p9 

    The article deals with the risks and complications associated with the use of drug-eluting stents for treating patients with cardiovascular diseases. Several clinical trial data have revealed that coated drug-eluting stents are linked with increased risk of late stent thrombosis as well as...

  • DAPT study expands to seven EU countries.  // Medical Device Daily;5/27/2010, Vol. 14 Issue 102, p2 

    The article focuses on the expansion of the dual antiplatelet therapy (DAPT) study to include participation from the Czech Republic, France, Germany, Hungary, Poland, Romania and Great Britain. The four-year clinical trial that investigates the duration of DAPT after the implantation of...

  • Longer and better studies on coronary stents required says FDA.  // Reactions Weekly;4/19/2008, Issue 1198, p1 

    The article reports on the issuance by the U.S. Food and Drug Administration (FDA) of a guidance on the testing and development of stents. The guidance suggests that all clinical trials should extend the follow-up period to 12 months. It also recommends that drug-eluting stent studies should be...


Read the Article


Sign out of this library

Other Topics